Xenon Pharmaceuticals (XENE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.11
- EPS estimate
- −$1.14
- EPS surprise
- +2.76%
- Revenue surprise
- −100.00%
- Revenue
- $0.00
- Revenue estimate
- $1.7M
- Reported
- Aug 6, 2026
Xenon Pharmaceuticals reported Q2 2026 results on August 6, 2026. It posted a loss of $1.11 per share, slightly narrower than the $1.14 loss analysts expected, a beat of 2.76%. No revenue was reported for the quarter, against a $1.7 million estimate. In Q2 2025, the loss was $1.07 per share, so the loss widened by about 3.7%.
Every quarter in the table is a loss, and losses have grown over time. Annual losses were $2.04 per share in 2022, $2.72 in 2023 and $3.02 in 2024. The table has no Q4 2025 row, so 2025 has no full-year total here. The widest quarterly loss in the table was $1.17 in Q1 2026. Revenue appears only in some quarters and is blank in most recent ones. The latest figure shown is $7.5 million in Q1 2025. Over the 20 quarters in the table, Xenon beat the EPS estimate 12 times and missed it eight times.
Xenon reported Q3 results between November 3 and November 12 in each of the past five years. That points to early or mid-November 2026 for the next report, which will show where the loss per share lands against recent quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$1.14 | −$1.11 | +2.76% | $0.00 | SEC |
| Q1 2026 | May 7, 2026 | −$1.18 | −$1.17 | +0.81% | $0.00 | SEC |
| Q3 2025 | Nov 3, 2025 | −$1.15 | −$1.15 | +0.21% | $0.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.99 | −$1.07 | −8.37% | $0.00 | SEC |
| Q1 2025 | May 12, 2025 | −$0.90 | −$0.83 | +7.39% | $7.5M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.86 | −$0.84 | +2.38% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.82 | −$0.81 | +0.69% | $0.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.70 | −$0.75 | −7.11% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.66 | −$0.62 | +6.65% | $0.00 | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.76 | −$0.64 | +15.70% | $0.00 | SEC |
| Q3 2023 | Nov 8, 2023 | −$0.77 | −$0.73 | +5.68% | $0.00 | SEC |
| Q2 2023 | Aug 9, 2023 | −$0.70 | −$0.72 | −3.36% | $0.00 | SEC |
| Q1 2023 | May 9, 2023 | −$0.62 | −$0.63 | −1.45% | $0.00 | SEC |
| Q4 2022 | Mar 1, 2023 | −$0.58 | −$0.57 | +2.55% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.52 | −$0.57 | −9.62% | $132,000.00 | SEC |
| Q2 2022 | Aug 9, 2022 | −$0.48 | −$0.55 | −13.87% | $536,000.00 | SEC |
| Q1 2022 | May 10, 2022 | −$0.41 | −$0.35 | +13.71% | $8.8M | SEC |
| Q4 2021 | Mar 1, 2022 | −$0.37 | −$0.48 | −29.35% | $3.7M | SEC |
| Q3 2021 | Nov 10, 2021 | −$0.38 | −$0.36 | +6.08% | $8.1M | SEC |
| Q2 2021 | Aug 11, 2021 | −$0.48 | −$0.51 | −6.52% | $2.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Xenon Pharmaceuticals (XENE) last report earnings?
Xenon Pharmaceuticals last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did XENE beat earnings estimates?
Yes. Xenon Pharmaceuticals reported EPS of −$1.11 for Q2 2026 against a −$1.14 estimate — a 2.76% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.